Manufacturing Digital's top 10 biggest pharmaceutical manufacturers delivering innovative healthcare and improved patient ...

A Delaware district court must maintain its pause of an order that the FDA delay final approval of MSN Laboratories Pvt. Ltd.

MSN Laboratories Pvt. Ltd. is appealing rulings that block the early launch of its copy of Entresto and preserve Novartis ...

While Novartis holds a diversified product portfolio, there is some product concentration with its largest drugs, Entresto (close to 15% of sales) and Cosentyx (close to 10% of sales). Both drugs will ...

Novartis raises 2025 sales and profit forecast as key drugs drive strong Q1 results; core operating income up 23% to $5.6 ...

The Swiss pharma company also raised its full-year guidance, with sales expected to grow by high-single digits and core ...

Novartis raised its 2025 outlook after its core operating profit rose 23% on year, boosted by strong demand for its key drugs ...

Novartis raised its 2025 outlook after high demand for key drugs drove first-quarter profit and sales above expectations, becoming the first among peers to lift forecasts this quarter despite looming ...

Novartis AG raised its outlook for the year after profit beat estimates in the first quarter, driven by medicines for breast ...

Swiss pharmaceutical firm Novartis on Tuesday reported better-than-expected first-quarter sales and raised its full-year ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

In 2024, the U.S. healthcare industry spent $6.1 billion on Pfizer’s COVID-19 therapy Paxlovid, a 6,922.8% increase from 2023 expenditure data, according to a recent study. The research, published ...